Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan Cancer Center; University of Michigan Rogel Cancer Center
• Treatments: Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide; Isophosphamide mustard; Lenograstim; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• no evidence of metastasis

• soft tissue sarcoma

• intermediate or high histologic grade

• greater than 5 cm

• Zubrod performance status 1 or better

• age 10 or older

Exclusion Criteria:

• clear cell, alveolar soft part, Ewing's rhabdosarcoma, undifferentiated small cell or Kaposi's

• prior chemotherapy

• nephrectomy

• active unstable angina pectoris

• concurrent therapy